Cas:2223-82-7 Neopentylglycol diacrylate manufacturer & supplier

Chemical Name:Neopentylglycol diacrylate

CAS.NO:2223-82-7

Synonyms:1,3-Bis(acryloyloxy)-2,2-dimethylpropane;2,2-Dimethylpropanediacrylate;2,2-dimethylpropane-1,3-diyl bisprop-2-enoate;viscoat247;EINECS 218-741-5;dimethylolpropanediacrylate;2,2-Dimethylpropanediol Diacrylate;Neopentylene glycol diacrylate;2,2-Dimethylpropane-1,3-diyl bisacrylate;2,2-dimethyl-1,3-propanediol diacrylate;2,2-Dimethyl-1,3-propanediyl bisacrylate;2-propenoic acid 2,2-dimethyl-1,3-propanediyl ester;NEOPENTGLYCOL DIACRYLATE;Neopentyl glycol dia;2-Propenoic acid, 2,2-dimethyl-1,3-propanediyl ester;neopentyl glycol diacrylate;NEOPENTANEDIOLDIACRYLATE;2,2-dimethyl-1,3-propanediyl diacrylate;2,2-Dimethylpropane-1,3-diol diacrylate;LIGHT ACRYLATE NP-A;2,2-dimethyltrimethyleneacrylate;MFCD00048148;Neopentylglycol diacrylate;sr247

Molecular Formula:C₁₁H₁₆O₄

Molecular Weight:212.242

HS Code:2916190090

Physical and Chemical Properties:

Melting point:N/A

Boiling point:267.9±13.0 °C at 760 mmHg

Density:1.0±0.1 g/cm3

Index of Refraction:1.452

PSA:52.60000

Exact Mass:212.104858

LogP:1.86

Material Safety Information (Applicable for Hazard Chemicals)

RIDADR:UN 2810 6.1/PG 2

Packing Group:III

Contact us for information like 1,3-Bis(acryloyloxy)-2,2-dimethylpropane chemical properties,Structure,melting point,boiling point,density,molecular formula,molecular weight,sr247 physical properties,toxicity information,customs codes,safety, risk, hazard and MSDS, CAS,cas number,LIGHT ACRYLATE NP-A Use and application,2,2-Dimethylpropanediol Diacrylate technical grade,usp/ep/jp grade.

Related News: Eli Lilly and Roche have been riding high this week on the controversial approval of Biogen’s anti-amyloid Alzheimer’s disease drug Aduhelm (aducanumab), as its new low bar could help these Big Pharmas jump the finish line. Neopentylglycol diacrylate manufacturer One key question for the fixed-duration combo is whether it can sustain remission after treatment has stopped. In the preliminary analysis of the GLOW trial, at three months after treatment ended, 51.9% of the Imbruvica-Venclexta patients had undetectable measurable residual disease (uMRD)—a stringent marker reflecting no signs of cancer—in bone marrow, versus 17.1% for the control group. The rates for peripheral blood were 54.7% and 39% for the two groups, respectively. Neopentylglycol diacrylate supplier With the advancement of supply-side structural reforms, the production of bulk APIs in China will become more concentrated, and the technology will be further improved. Neopentylglycol diacrylate vendor Patents covering oral and injectable rigosertib have been issued in the US and are expected to provide coverage until at least 2037. Neopentylglycol diacrylate factory Patents covering oral and injectable rigosertib have been issued in the US and are expected to provide coverage until at least 2037.